LifeVantage (LFVN) Q4 2026 earnings review
Revenue Collapse Continues While Guidance is Suspended Amidst CEO Transition
LifeVantage's Q4 results capped a disastrous fiscal 2026, with revenue plunging 23.1% YoY to $42.4 million. The narrative remains dominated by the spectacular collapse of the MindBody GLP-1 System, which failed to compete with pharmaceutical alternatives, triggering a massive ongoing exodus of active consultants and customers. New CEO Terrence Moorehead inherits a completely debt-free balance sheet and a company that managed to stay profitable through strict cost controls, but the decision to suspend FY27 guidance highlights a severe lack of forward visibility. The core direct-selling network is eroding rapidly.
🐂 Bull Case
Despite a $45.9M YoY drop in annual sales, management successfully slashed SG&A and variable compensation, preserving $5.1M in GAAP Net Income and $13.7M in Adjusted EBITDA for the year. The company remains highly cash-generative relative to its size.
New CEO Terrence Moorehead starts with $14.9M in cash, zero debt, and an active share repurchase program. The operational slate is clean to attempt a brand pivot.
🐻 Bear Case
The lifeblood of the business—active consultants—dropped 15.7% YoY to 43,000. Total active customers plummeted 24.7%. Without a stable base, reversing revenue declines will be nearly impossible.
Using a CEO transition as a shield to suspend FY27 guidance suggests management currently has no reliable baseline for when the revenue bleeding will find a floor.
⚖️ Verdict: 🔴🔴
Bearish. A direct-selling business relies entirely on its network momentum. A 21.2% total drop in active accounts and an abrupt suspension of guidance outweighs the debt-free balance sheet.
Key Themes
Erosion of the Direct-Selling Network
Total Active Accounts fell aggressively, decelerating to 104,000 from 132,000 a year ago (-21.2%). Crucially, Active Independent Consultants—the primary sales engine—shrank 15.7% globally. The Americas region was hit hardest with a 24.0% decline in total accounts. The core foundation of the business model is eroding.
The MindBody GLP-1 Hangover
The company continues to suffer brutal YoY comparisons due to the spectacular failure of its MindBody GLP-1 System. Originally touted as a massive growth driver in late FY25, it was quickly decimated by pharmaceutical alternatives. The fallout continues to drag down both revenue volume and gross margins (due to inventory obsolescence).
LoveBiome Acquisition Defending Against Total Collapse
Sales of LoveBiome, acquired in October 2025, remain the lone bright spot mentioned by management, partially offsetting the massive declines across the rest of the Americas and Asia/Pacific portfolios. Without it, the 20.1% full-year revenue drop would have been even steeper.
Aggressive Cost Controls Preserving Bottom Line
Management successfully scaled down variable expenses to match the shrinking topline. Q4 commissions and incentives fell $5.7M YoY (dropping to 41.3% of revenue), and SG&A was slashed by $4.8M YoY. This structural flexibility prevented the company from swinging to an operating loss amidst a >20% revenue contraction.
Margin Compression Reversing Historic Gains
Gross margin dropped to 78.0% in Q4 (down from 79.9% a year ago). Management cited unfavorable product mix shifts, persistent inventory obsolescence expenses (lingering from the MindBody rollout), and rising shipping costs. This represents a reversal of the margin expansion story touted in FY25.
Other KPIs
Decelerating. Cash from operations fell from $11.9 million in FY25 to $10.2 million in FY26. However, given the severe drop in revenue, maintaining positive cash flow demonstrates effective working capital management and tight control over inventory and receivables during a turbulent period.
Decelerating. Cut nearly in half from $4.8 million in the prior year period. Full-year Adjusted EBITDA fell to $13.7M from $22.1M. The operational leverage that worked in their favor during the FY25 run-up is now actively working against them as volumes contract.
Guidance
Reversing. Citing the 'recent transition in the Chief Executive Officer role,' the company explicitly declined to issue formal guidance for the upcoming fiscal year. This lack of transparency typically implies that internal stabilization has not yet been achieved.
Key Questions
Consultant Retention Strategy
With the consultant base shrinking 15.7% year-over-year, what specific, immediate actions is new CEO Terrence Moorehead taking to halt the exodus and rebuild trust in the field?
MindBody GLP-1 Inventory
Gross margins remain pressured by inventory obsolescence. Have we completely written down the excess inventory from the MindBody GLP-1 System, or should we expect further margin drags in FY27?
LoveBiome Synergy Visibility
With the core portfolio shrinking rapidly, what is the exact revenue contribution of the LoveBiome acquisition, and is the cross-selling strategy actually materializing among the legacy consultant base?
Guidance Resumption Timeline
Given the suspension of FY27 guidance, what internal operational milestones or baseline stability metrics must be achieved before management feels confident enough to reinstate forward-looking targets?